Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer

Oncology (Switzerland)

Volumn 84, Issue 2, 2012, Pages 100-107

  Inoue, Yasuhiro ^a   Iwata, Takashi ^a   Okugawa, Yoshinaga ^a   Kawamoto, Aya ^a   Hiro, Junichiro ^a   Toiyama, Yuji ^a   Tanaka, Koji ^a   Uchida, Keiichi ^a   Mohri, Yasuhiko ^a   Miki, Chikao ^b   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Surgery   (Japan)

Author keywords

C reactive protein; Colorectal cancer; Glasgow Prognostic Score

Indexed keywords

BEVACIZUMAB; C REACTIVE PROTEIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; INOPERABLE CANCER; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RATING SCALE; RETROSPECTIVE STUDY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84868603083     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000343822     Document Type: Article

References (28)

1. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
2. Falcone A, Ricci S, Brunetti I, Pfanner E, Al-legrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leu-covorin, oxaliplatin, and irinotecan (FOLF-OXIRI) compared with infusional fluoro-uracil, leucovorin, and irinotecan (FOL-FIRI) as first-line treatment for metastatic colorectal cancer. J Clin Oncol 2007; 25: 1670-1676.
3. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
4. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
5. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, leucov-orin, and oxaliplatin with and without ce-tuximab in the first-line treatment of meta-static colorectal cancer. J Clin Oncol 2009; 27:663-671.
6. Kusunoki M, Noda M, Yanagi H, Kotera H, Yamamura T: Second-look hepatectomy after 5-FU arterial infusion in patients with primary unresectable hepatic colorectal metastases: molecular characteristics of the tumors. Int J Oncol 1997; 10:107-111.
7. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR: Improved surv iva l in metastatic colorec tal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
8. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kab-binavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A: Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14: 862-870.
9. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH: Tumour response and secondary resect-ability of colorectal liver metastases following neoadjuvant chemotherapy with cetu-ximab: the CELIM randomized phase 2 trial. Lancet Oncol 2010; 11:38-47.
10. Inoue Y, Hiro J, Toiyama Y, Tanaka K, Mohri Y, Kusunoki M: Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer. Oncol Letters 2012; 3: 363-368.
11. Koike Y, Miki C, Okugawa Y, Yokoe T, Toi-yama Y, Tanaka K, Inoue Y, Kusunoki M: Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol 2008; 98: 540-544.
12. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M: C-react ive protein as a prog-nost ic va r iable t hat ref lect s uncont rol led up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 2004; 49: 970-976.
13. Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, Todo M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Ochiai T, Koku-ba Y, Sonoyama T, Otsuji E: Elevated serum CRP levels after induction chemoradiother-apy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 2011; 103: 62-68.
14. Shimura T, Kitagawa M, Yamada T, Ebi M, Mizoshita T, Tanida S, Kataoka H, Kamiya T, Joh T: C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res 2012; 32: 491-496.
15. Elahi MM, McMillan DC, McArdle CS, An-gerson WJ, Sattar N: Score based on hypoal-buminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 2004; 48:171-173.
16. Brown DJ, Milroy R, Preston T, McMillan DC: The relationship between an inflammation based prognostic score (GPS) and changes in serum biochemical variables in patients with advanced lung a nd gastroi ntes-tinal cancer. J Clin Pathol 2006; 60:705-708.
17. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC: Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006; 94: 637-641.
18. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ: Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006; 6:450-453.
19. Read JA, Choy ST, Beale PJ, Clarke SJ: Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer 2006; 55:78-85.
20. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC: Eva luation of an inf lamma-tion-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109: 205-212.
21. Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohr i Y, Ku su nok i M: Eva luat ion of in f lam-mation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorec-tal cancer. Exp Ther Med 2011; 2:95-101.
22. McMillan DC, Canna K, McArdle CS: Systemic inflammatory response predicts survival following curative resection for colorecta l cancer. Br J Surg 2003; 90: 215-219.
23. Crozier JE, McKee RF, McArdle CS, Anger-son WJ, Anderson JH, Horgan PG, McMillan DC: The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer 2006; 94: 1833-1836.
24. Forrest LM, McMillan DC, McArdle CS, An-gerson WJ, Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003; 89:1028-1030.
25. Ishizuka M, Kita J, Shimoda M, Rokkaku K, Kato M, Sawada T, Kubota K: Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J Surg Oncol 2009; 100:38-42.
26. Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Miki K, Kobayashi K, Morita K: Elevated C-reactive protein and hypo-albuminemia measured before resection of colorectal liver metastases predict postoperative survival. Dig Surg 2010; 27:285-290.
27. Kobayashi T, Teruya M, Kishiki T, Endo D, Ta kena k a Y, Ta na ka H, Mik i K, Kobayashi K, Morita K: Inflammation-based prognostic score, prior to neoadjuvant chemoradiother-apy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surger y 2008; 144: 729-735.
28. Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, Todo M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Ochiai T, Koku-ba Y, Sonoyama T, Otsuji E: Elevated serum CRP levels after induction chemoradiother-apy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 2011; 103: 62-68.